Advertisement

NLS non-valvular atrial fibrillation

Clinical Trials - May 18, 2015

Solid Safety Profile for Heart Drug

New data from an ongoing post-marketing study evaluating the safety of once-daily XARELTO® (rivaroxaban) in patients with non-valvular atrial fibrillation (NVAF) were presented at the American Geriatrics Society 2015 Annual Scientific Meeting. “The data from this ongoing five-year observational study reaffirms the safety profile of XARELTO®, including in elderly patients who are at a particularly […]

Sign up to our Newsletter!

I confirm that I want to subscribe to newsletters from Nordic Life Science and that Nordic Life Science has the right to save my email address. Read our privacy policy here

Read the latest issue!

Sign up for a subscription and read our latest digital issue today.

Sign up
Sign up

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.